LV11952B - HEMATOPORFIRINE COMPOUND SALTS, DERIVATIVES AND USE FOR DETERMINATION AND TREATMENT OF TAILS - Google Patents
HEMATOPORFIRINE COMPOUND SALTS, DERIVATIVES AND USE FOR DETERMINATION AND TREATMENT OF TAILS Download PDFInfo
- Publication number
- LV11952B LV11952B LVP-97-110A LV970110A LV11952B LV 11952 B LV11952 B LV 11952B LV 970110 A LV970110 A LV 970110A LV 11952 B LV11952 B LV 11952B
- Authority
- LV
- Latvia
- Prior art keywords
- carboxy
- formula
- ethylamino
- mixture
- salts
- Prior art date
Links
- -1 COMPOUND SALTS Chemical class 0.000 title claims abstract description 51
- 150000003839 salts Chemical class 0.000 claims abstract description 76
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 22
- 229960003569 hematoporphyrin Drugs 0.000 claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 238000001514 detection method Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000000178 monomer Substances 0.000 claims abstract description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract 4
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims description 49
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 13
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims description 10
- 229950003776 protoporphyrin Drugs 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 229940015493 dihematoporphyrin ether Drugs 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Chemical group 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000012456 homogeneous solution Substances 0.000 claims description 3
- 239000011833 salt mixture Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims 2
- XYFMWKVQFYKINJ-UHFFFAOYSA-N 1,2-dihydroimidazole-3-carboxylic acid Chemical compound OC(=O)N1CNC=C1 XYFMWKVQFYKINJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 239000007810 chemical reaction solvent Substances 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
- 125000003395 phenylethylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 16
- 150000002148 esters Chemical class 0.000 abstract description 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 238000009739 binding Methods 0.000 abstract 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 73
- 239000000243 solution Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
- 230000001613 neoplastic effect Effects 0.000 description 6
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 5
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 5
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 5
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 5
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- ANWNNZDPJNWHNX-UHFFFAOYSA-N [N]1C2=CC=C1C=C(N1)C(O)=C(C(=O)O)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 Chemical compound [N]1C2=CC=C1C=C(N1)C(O)=C(C(=O)O)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 ANWNNZDPJNWHNX-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000035269 cancer or benign tumor Diseases 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 3
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 3
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 101100341123 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) IRA2 gene Proteins 0.000 description 1
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical group N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL91292220A PL165249B1 (pl) | 1991-10-29 | 1991-10-29 | Sposób otrzymywania soli kompleksowych hematoporfiryny i jej pochodnych PL PL PL PL PL PL PL |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV11952A LV11952A (lv) | 1998-01-20 |
| LV11952B true LV11952B (en) | 1998-06-20 |
Family
ID=20055985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-97-110A LV11952B (en) | 1991-10-29 | 1997-06-05 | HEMATOPORFIRINE COMPOUND SALTS, DERIVATIVES AND USE FOR DETERMINATION AND TREATMENT OF TAILS |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5451599A (cs) |
| EP (1) | EP0539960B1 (cs) |
| JP (1) | JP3020759B2 (cs) |
| CN (1) | CN1040328C (cs) |
| BG (1) | BG61648B1 (cs) |
| CA (1) | CA2081605C (cs) |
| CZ (1) | CZ281694B6 (cs) |
| DE (1) | DE69217819T2 (cs) |
| DK (1) | DK0539960T3 (cs) |
| FI (1) | FI100243B (cs) |
| HR (1) | HRP921337B1 (cs) |
| LV (1) | LV11952B (cs) |
| NO (1) | NO300499B1 (cs) |
| PL (1) | PL165249B1 (cs) |
| RU (1) | RU2122003C1 (cs) |
| SI (1) | SI9200286B (cs) |
| UA (1) | UA40568C2 (cs) |
| YU (1) | YU48961B (cs) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| US5948771A (en) * | 1996-01-31 | 1999-09-07 | The Trustees Of Columbia University In The City Of New York | Method for treating heart failure using tetrapyrroles and metallotetrapyrroles |
| GB9606293D0 (en) * | 1996-03-26 | 1996-05-29 | William Harvey Research Limite | Treatment of cancers and other tumours |
| RU2164136C2 (ru) * | 1998-09-09 | 2001-03-20 | Государственный научный центр РФ "НИОПИК" | Фотосенсибилизатор для фотодинамической терапии |
| AU2002220853B2 (en) | 2000-11-29 | 2007-06-28 | Pci Biotech As | Photochemical internalization for delivery of molecules into the cytosol |
| AU2002222104B2 (en) | 2000-11-29 | 2007-06-28 | Pci Biotech As | Photochemical internalization for virus-mediated molecule delivery into the cyosol |
| RU2236411C2 (ru) * | 2002-06-06 | 2004-09-20 | Московская государственная академия тонкой химической технологии им. М.В. Ломоносова | Металлокомплексы карборанилпорфиринов, обладающие противоопухолевой активностью |
| RU2278119C1 (ru) * | 2004-12-06 | 2006-06-20 | Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" | Тетраазахлорины как фотосенсибилизаторы для фотодинамической терапии |
| RU2282647C1 (ru) * | 2005-05-31 | 2006-08-27 | Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") | Фотосенсибилизаторы для антимикробной фотодинамической терапии |
| RU2282646C1 (ru) * | 2005-05-31 | 2006-08-27 | Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") | Фотосенсибилизаторы для фотодинамической терапии |
| CN104130266A (zh) * | 2013-05-02 | 2014-11-05 | 中国医学科学院生物医学工程研究所 | 一种新型原卟啉衍生物及制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2912M (fr) * | 1963-07-24 | 1964-11-09 | Rech S Pharma E R P H A R Soc | Dichlorhydrate d'hématoporphyrinate de procaine. |
| US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| JPS60152487A (ja) * | 1984-01-18 | 1985-08-10 | Sato Yakugaku Kenkyusho:Kk | デユウテロポルフイリン誘導体及びその塩 |
| US4675338A (en) * | 1984-07-18 | 1987-06-23 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| GB8429845D0 (en) * | 1984-11-26 | 1985-01-03 | Efamol Ltd | Porphyrins & cancer treatment |
| US4977177A (en) * | 1985-04-30 | 1990-12-11 | Nippon Petrochemicals Company, Ltd. | Tetrapyrrole polyaminomonocarboxylic acid therapeutic agents |
| CA1291710C (en) * | 1985-04-30 | 1991-11-05 | Jerry C. Bommer | Tetrapyrrole therapeutic agents |
| EP0220686B1 (en) * | 1985-10-23 | 1992-12-30 | Nihon Medi-Physics Co., Ltd. | Porphyrin derivatives, and their production and use |
| US4882234A (en) * | 1986-11-12 | 1989-11-21 | Healux, Inc. | Storage-stable porphin compositions and a method for their manufacture |
| US4861876A (en) * | 1986-11-26 | 1989-08-29 | Wayne State University | Hematoporphyrin derivative and method of preparation and purification |
| JPH0786109B2 (ja) * | 1987-12-21 | 1995-09-20 | 浜理薬品工業株式会社 | フェオフォルバイド誘導体 |
| GB8805849D0 (en) * | 1988-03-11 | 1988-04-13 | Efamol Holdings | Porphyrins & cancer treatment |
| US5190966A (en) * | 1988-07-06 | 1993-03-02 | Health Research, Inc. | Purified hematoporphyrin dimers and trimers useful in photodynamic therapy |
| US4968715A (en) * | 1988-07-06 | 1990-11-06 | Health Research, Inc. | Use of purified hematoporphyrin trimers in photodynamic therapy |
| US4961920A (en) * | 1988-12-08 | 1990-10-09 | Luminis Pty, Ltd. | Phototherapeutic monovinyl and divinyl ether-linked dimers |
| US5059619A (en) * | 1989-06-14 | 1991-10-22 | Quadra Logic Technologies, Inc. | Stable freeze-dried polyhematoporphyrin ether/ester |
| US4965054A (en) * | 1989-08-01 | 1990-10-23 | Henkel Corporation | Process of extraction of gallium from aqueous solutions thereof |
| CN102565846B (zh) * | 2011-12-30 | 2014-05-14 | 清华大学 | 蜂窝型热中子探测器 |
-
1991
- 1991-10-29 PL PL91292220A patent/PL165249B1/pl not_active IP Right Cessation
-
1992
- 1992-10-26 FI FI924856A patent/FI100243B/fi not_active IP Right Cessation
- 1992-10-28 CA CA002081605A patent/CA2081605C/en not_active Expired - Lifetime
- 1992-10-28 RU RU92004314/04A patent/RU2122003C1/ru not_active IP Right Cessation
- 1992-10-28 NO NO924151A patent/NO300499B1/no not_active IP Right Cessation
- 1992-10-28 BG BG97030A patent/BG61648B1/bg unknown
- 1992-10-28 DK DK92118447.9T patent/DK0539960T3/da active
- 1992-10-28 DE DE69217819T patent/DE69217819T2/de not_active Expired - Lifetime
- 1992-10-28 EP EP92118447A patent/EP0539960B1/en not_active Expired - Lifetime
- 1992-10-29 SI SI9200286A patent/SI9200286B/sl not_active IP Right Cessation
- 1992-10-29 CN CN92112561A patent/CN1040328C/zh not_active Expired - Fee Related
- 1992-10-29 YU YU94592A patent/YU48961B/sh unknown
- 1992-10-29 JP JP4291322A patent/JP3020759B2/ja not_active Expired - Lifetime
- 1992-10-29 US US07/968,434 patent/US5451599A/en not_active Expired - Lifetime
- 1992-10-29 CZ CS923252A patent/CZ281694B6/cs not_active IP Right Cessation
- 1992-11-24 HR HRP-945A patent/HRP921337B1/xx not_active IP Right Cessation
-
1993
- 1993-06-15 UA UA93002921A patent/UA40568C2/uk unknown
-
1997
- 1997-06-05 LV LVP-97-110A patent/LV11952B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2081605C (en) | 2002-02-26 |
| UA40568C2 (uk) | 2001-08-15 |
| JP3020759B2 (ja) | 2000-03-15 |
| LV11952A (lv) | 1998-01-20 |
| DE69217819D1 (de) | 1997-04-10 |
| CZ281694B6 (cs) | 1996-12-11 |
| CZ325292A3 (en) | 1993-09-15 |
| HRP921337A2 (en) | 1994-10-31 |
| RU2122003C1 (ru) | 1998-11-20 |
| EP0539960A3 (en) | 1993-06-16 |
| SI9200286B (en) | 2001-06-30 |
| NO300499B1 (no) | 1997-06-09 |
| YU48961B (sh) | 2003-01-31 |
| DE69217819T2 (de) | 1997-09-04 |
| PL165249B1 (pl) | 1994-11-30 |
| FI924856A0 (fi) | 1992-10-26 |
| DK0539960T3 (da) | 1997-09-15 |
| FI100243B (fi) | 1997-10-31 |
| EP0539960B1 (en) | 1997-03-05 |
| SI9200286A (en) | 1993-06-30 |
| NO924151D0 (no) | 1992-10-28 |
| JPH05262775A (ja) | 1993-10-12 |
| CN1071914A (zh) | 1993-05-12 |
| FI924856A7 (fi) | 1993-04-30 |
| PL292220A1 (en) | 1993-09-20 |
| HRP921337B1 (en) | 2000-02-29 |
| YU94592A (sh) | 1995-12-04 |
| BG61648B1 (bg) | 1998-02-27 |
| NO924151L (no) | 1993-04-30 |
| EP0539960A2 (en) | 1993-05-05 |
| US5451599A (en) | 1995-09-19 |
| BG97030A (bg) | 1994-03-24 |
| CN1040328C (zh) | 1998-10-21 |
| CA2081605A1 (en) | 1993-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2291759T3 (es) | Ligandos piridino pentaazamacrociclicos sustituidos. | |
| EP0322795B1 (en) | Novel tetrapyrrole aminocarboxylic acids | |
| CA1315780C (en) | Porphyrin derivatives | |
| ES2257858T3 (es) | Porfirinas sustituidas. | |
| LV11952B (en) | HEMATOPORFIRINE COMPOUND SALTS, DERIVATIVES AND USE FOR DETERMINATION AND TREATMENT OF TAILS | |
| AU2001272463B2 (en) | Substituted metal-phthalocyanines, their preparation and the use thereof | |
| KR102245556B1 (ko) | 신규 클로린 e6 유도체 및 이의 약학적으로 허용가능한 염, 이의 제조방법 및 응용 | |
| WO1994000118A1 (en) | Production and use of imines of porphyrins | |
| CN101863788B (zh) | 5-氨基乙酰丙酸盐、其制备方法及其用途 | |
| CA2093361C (en) | Porphyrin derivative | |
| US7276494B2 (en) | Photosensitisers | |
| CN113831351A (zh) | 一类新型四吡咯衍生物及其应用 | |
| Reshetnickov et al. | Novel drug form of chlorin e6 | |
| JP5372371B2 (ja) | カチオン性バクテリオクロロフィル誘導体及びその使用 | |
| EP0837839A2 (en) | 9-substituted porphycenes | |
| CN1942430B (zh) | 5-氨基乙酰丙酸盐、其制备方法及其用途 | |
| WO1994017077A1 (fr) | Composition inhibitrice active d'oxygene | |
| WO1998015271A1 (en) | 9-substituted porphycenes | |
| CA2133284A1 (en) | Octacarboxy substituted tetra(2,3-pyrazino)porphyrazines and their derivatives |